A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

  • End date
    Nov 22, 2026
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 22 October 2022


The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

Condition Metastatic Colorectal Cancer
Treatment fluorouracil, bevacizumab, Irinotecan, Leucovorin, Magrolimab
Clinical Study IdentifierNCT05330429
SponsorGilead Sciences
Last Modified on22 October 2022


Yes No Not Sure

Inclusion Criteria

Previously treated individuals with inoperable metastatic colorectal cancer (mCRC) who are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or mismatch repair deficient (dMMR) and are excluded)
Histologically or cytologically confirmed adenocarcinoma originating in the colon or rectum (excluding appendiceal and anal canal cancers), who have progressed on or after 1 prior systemic therapy with chemotherapy based on 5-fluorouracil (5-FU) with oxaliplatin and bevacizumab
Measurable disease (RECIST V1.1 criteria)
Individuals must have an eastern cooperative oncology group (ECOG) performance status of 0 or 1
Life expectancy of at least 12 weeks
Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and platelet counts
Adequate liver function
Adequate renal function

Exclusion Criteria

Prior anticancer therapy including chemotherapy, hormonal therapy, or investigational agents within 3 weeks or within at least 4 half-lives prior to magrolimab dosing (up to a maximum of 4 weeks), whichever is shorter
Known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E or MSI-H mutations or dMMR
Persistent Grade 2 or more gastrointestinal bleeding
Individuals with prior irinotecan therapy
Individuals without prior bevacizumab therapy for colorectal cancer
Clinically significant coronary artery disease or myocardial infarction within 6 months prior to inclusion
Peripheral neuropathy of more than Grade 1 (CTCAE Version 5.0)
Known dihydropyrimidine dehydrogenase deficiency
Acute intestinal obstruction or subobstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colic prosthesis
Unhealed wound, active gastric or duodenal ulcer, or bone fracture
History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4 gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominal abscesses 6 months prior to screening
Uncontrolled arterial hypertension
Thromboembolic event in the 6 months before inclusion (eg, transitory ischemic stroke, stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosis treated with anticoagulants
Active central nervous system (CNS) disease. Individuals with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed
Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening
History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months
Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient
Known inherited or acquired bleeding disorders
Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study
Second malignancy, except treated basal cell or localized squamous skin carcinomas, or localized prostate cancer
Known active or chronic hepatitis B or C infection or HIV infection in medical history
Uncontrolled pleural effusion
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note